MAXCYTE, INC.

Share Issue/Capital Change • Dec 1, 2021

National Storage Mechanism | Additional information

RNS Number : 2758U

MaxCyte, Inc.

01 December 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Gaithersburg, Maryland - 1 December 2021:   MaxCyte (LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, it has recently issued 34,568 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options. The new Common Stock will rank pari passu with the existing shares of common stock of the Company.

As of 30 November 2021, the total issued stock capital of the Company following the recent issue of the new Common Stock is 101,202,705 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 100,872,705 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' is 330,000.  

For further information, please contact:

	MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 [email protected]
	Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
	UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 [email protected]

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKDBNABDDNBK